For patients with chronic hepatitis C, there is a significantly greater risk for developing parkinsonism, however, treatment with PegIFN/RBV may reduce this risk.
For patients with chronic hepatitis C, there is a significantly greater risk for developing parkinsonism, however, treatment with PegIFN/RBV may reduce this risk.